Westlake BioPartners®

I’m pleased to share that Novartis has acquired Kate Therapeutics. This is an exciting deal that bolsters our pipeline and brings expertise and capabilities that complement our work to advance novel gene therapies with transformative potential for people with inherited neuromuscular diseases.   We believe that Kate's innovative technology platforms, combined with our scientific expertise, leadership and ongoing internal efforts in gene therapy and neuroscience, will position us well to address some of the limitations of existing gene therapies and bring new options to patients with these disorders.   Thank you to the teams at both Novartis and Kate who worked so hard to get this acquisition across the finish line.  https://lnkd.in/enaNj_qg

We are very pleased to announce the appointment of Tim Walbert as the new Chairman of the Board of Directors at Latigo! Tim is a highly respected leader in the biopharmaceutical sector, most recently serving as chairman, president, and CEO of Horizon Therapeutics, which was acquired by Amgen for over $28 billion. He brings a wealth of experience and a stellar track record, having led IDM Pharma to its acquisition by Takeda and orchestrated the global launch of HUMIRA® at Abbott, alongside influential roles at several other top-tier companies. Our CEO, Nima Farzan, expressed his enthusiasm about Tim’s appointment, stating, “Tim’s proven ability to build successful biopharma companies and his dedication to patient-centered innovation align perfectly with our mission to deliver effective and safer alternatives for individuals suffering from acute and chronic pain.” A heartfelt thank you to our previous Chair, Nancy Stagliano, whose invaluable guidance has been instrumental in establishing our company and advancing our mission. To read the full announcement, click here: https://lnkd.in/gHJFupPx #BioPharma #Biotech #BiotechNews

We are excited to announce the appointment of Tim Lugo as our new Chief Financial Officer and the addition of Beth Seidenberg, M.D., and Jim Tananbaum, M.D., to our board of directors. Tim brings over two decades of experience in biotechnology finance and equity research, while Dr. Seidenberg and Dr. Tananbaum are seasoned venture capitalists. Their expertise will be instrumental as we scale and accelerate the development of our non-opioid pain medicines. Welcome to the Latigo Biotherapeutics, Inc. team! Click the link below to read the full press release. 👇 https://lnkd.in/gHJFupPx #NonOpioidPainRelief #Leadership #BioPharma

We are excited to announce our $325 million #SeriesC financing.  This new investment will enable ArsenalBio's ongoing development efforts and scale our manufacturing capabilities to develop T-cell medicines.  We thank the new investors along with our existing investors for their support in helping us to achieve our goal to defeat cancer. #celltherapy #patientsfirst https://lnkd.in/dimnsnfm

Today, we announced new Phase 1 data about the safety and tolerability of our therapeutic approach that may provide pain patients with an alternative to opioids. LTG-001 is an oral, selective Nav1.8 inhibitor in development to treat acute and chronic pain at its source. Opioid addiction is a national public health concern – 3.75 million Americans go on to long-term chronic opioid use after low-risk surgery as up to 19% of patients exposed to opioids develop dependency. We are also thrilled to welcome world-renowned analgesic scientist Neil Singla, MD as our chief medical officer. Learn more about these results and our commitment to provide effective, rapid-acting pain relief without the risk of addiction. https://lnkd.in/guXWFrrv #BioPharma #Biotechnology #Pharma #News #PainManagement #NonOpioid

Thanks to Nasdaq for their recognition of our recent launch! Westlake Village BioPartners®, 5AM Ventures, Foresite Capital, Corner Ventures #NASDAQ

Today, Boehringer Ingelheim and 3T Biosciences are pleased to announce a second partnership focused on discovering and developing next-generation #cancer #immunotherapies.    This new collaboration It brings together 3T’s best-in-class 3T-TRACE discovery platform with Boehringer Ingelheim’s commitment to develop first-in-class immuno-oncology treatments that boost the immune system’s ability to recognize, attack and kill tumors.   Read more about this collaboration in our press release: https://lnkd.in/griNxiqm